159 filings
Page 3 of 8
8-K
p7uyhq 6mjf
23 Dec 21
Departure of Directors or Certain Officers
5:09pm
8-K
g38hksh mdbii
10 Dec 21
Blueprint Medicines Appoints Daniella Beckman to its Board of Directors
12:00am
8-K
i9smrs zzoxxmdw4d9
29 Nov 21
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
7:04am
8-K
ntwz s4zo1
9 Nov 21
Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
8:39am
8-K
01vpu1rn4puhm
28 Oct 21
Blueprint Medicines Reports Third Quarter 2021 Financial Results
7:48am
8-K
6r1ohi ycip
29 Jul 21
Blueprint Medicines Reports Second Quarter 2021 Financial Results
7:15am
8-K
q3ow owwjsx742wh4t8b
28 Jul 21
Other Events
4:15pm
8-K
k5nasjhnx s7can3hoa
16 Jun 21
FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
5:14pm
8-K
ptv0tpqcsoy rwst6dl
4 Jun 21
Submission of Matters to a Vote of Security Holders
4:21pm
8-K
p6gl2iyq7wpsiwdyn6
17 May 21
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
8:30am
8-K
e4b2 1b3u1
29 Apr 21
Blueprint Medicines Reports First Quarter 2021 Financial Results
7:40am
8-K
8l7xe2ke1jgu22 zi
12 Apr 21
Regulation FD Disclosure
7:40am
8-K
wajq5rxfpshtn
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
8-K
qwzfnm
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
8-K
n3dnzahqko 6jvz
17 Dec 20
Other Events
4:15pm
8-K
0rx95 dc117284n7
1 Dec 20
Other Events
4:23pm
8-K
ozzgi
29 Oct 20
Blueprint Medicines Reports Third Quarter 2020 Financial Results
8:00am
8-K
zclkc6k
22 Sep 20
Regulation FD Disclosure
8:20am
8-K
9xskoeenlkmc5vn rr
21 Sep 20
Other Events
8:00am
8-K
qteae2
8 Sep 20
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment
6:03am